Does MPLT pay a dividend?

The cached stock data on this page does not show a positive dividend yield for MPLT. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does MPLT stock do?

Clinical-stage biopharmaceutical company focused on developing neural circuit-targeted therapeutics for central nervous system (CNS) disorders, currently pre-revenue with zero commercial sales.

What is MPLT stock's price target?

This cached page does not contain a precise model fair value for MPLT.

The TradeMates model verdict for MPLT is HOLD with an investment score of 40/100. Treat this as a model signal to review, not a personal buy recommendation.

Is MPLT a good dividend stock?

MPLT is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

MPLT (MPLT) Stock Analysis

Q: Is MPLT stock a good investment?

The cached TradeMates AI model rates MPLT as HOLD with an investment score of 40/100. The model score of 40/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.

Verdict: HOLD

Strong 40-month cash runway provides CNS trial buffer, but peak insider dumping and analyst downgrades highlight elevated execution risk.

Investment score: 40/100

The model score of 40/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.

Peers

SGMT
CBIO
ALT
CTMX
STTK

Peer	P/E	P/B	P/S	EV/EBITDA	ROIC %	Net margin %
SGMT	-8.17	2.17	0.00	-3.56	—	0.00
CBIO	-2.27	3.21	53.70	-2.87	—	-13.72
ALT	-4.15	1.27	20325.67	-6.51	—	-2960.00
CTMX	-6.14	2.00	32.89	-7.55	—	-4.35
STTK	-11.53	3.61	531.39	-9.72	—	-52.57

View the full interactive analysis